Streetbeat News

Products Services

MFC

Manulife (NYSE:MFC) and its subsidiary John Hancock have initiated a five-year research collaboration with MIT AgeLab, focusing on longevity innovation. This partnership aims to generate actionable insights for businesses, policymakers, and families, reinforcing Manulife's commitment to enhancing life quality for the aging population.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:34 pm

GOOG

GOOGL

IGM

XLC

U.S. auto safety regulators are investigating Alphabet Inc's Waymo self-driving vehicles for potential traffic safety law violations after 22 incidents, including 17 collisions. The National Highway Traffic Safety Administration (NHTSA) is examining Waymo's 5th Generation automated driving system's performance in detecting and responding to traffic control devices. This investigation also includes other companies like GM's Cruise and Amazon's Zoox. Waymo has recalled 444 vehicles due to software errors in February and is cooperating with NHTSA.

Portfolio Pulse from Shivani Kumaresan

May 14, 2024 | 2:28 pm

ANY

Sphere 3D reported mining 29.9 Bitcoin in April 2024 and plans to pursue cost reduction opportunities in operations and SG&A. The company anticipates volatility in Bitcoin production as it executes strategic steps.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:18 pm

AFMD

Affimed N.V. announced the acceptance of an abstract on preclinical data of its CD16A/CD123-targeting innate cell engager, AFM28, for presentation at the EHA 2024 Congress. The data demonstrates AFM28's effectiveness in controlling tumor growth and reducing leukemic blasts and stem cells in AML models.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:12 pm

GMAB

Genmab announced the presentation of multiple abstracts on Epcoritamab at the 2024 European Hematology Association Congress scheduled for June 13-16. This event could highlight the potential of Epcoritamab in treating hematological malignancies and may influence Genmab's research and development direction.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:10 pm

GMAB

Genmab announced the presentation of multiple abstracts on Epcoritamab at the 2024 European Hematology Association Congress scheduled for June 13-16, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:09 pm

ACET

Adicet Bio, Inc. (NASDAQ:ACET), a biotech company, announced its participation in the 2024 EHA Hybrid Congress with a poster presentation on ADI-270, a therapy for cancer. The presentation will detail ADI-270's design for treating various cancer types and marks a significant step in the company's research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:07 pm

POET

POET Technologies Inc. (NASDAQ:POET) has been selected by Foxconn Interconnect Technology to supply silicon photonics integrated circuits (Silicon PIC) for 800G and 1.6T optical transceiver modules. This partnership aims to serve advanced AI and high-speed data center networks. POET will provide optical engines using its Optical Interposer technology, contributing to a market expected to grow at a 33% CAGR, reaching $10.5 billion by 2029. The design completion for these optical engines is anticipated by Q3 2024, with production starting in Q4 2024 at Super Photonics Xiamen, a joint venture. POET's stock saw a 9.59% increase to $2.38.

Portfolio Pulse from Akanksha Bakshi

May 14, 2024 | 2:06 pm

AUTL

Autolus Therapeutics plc (NASDAQ:AUTL) announced the online publication of three abstracts on obe-cel for treating relapsed/refractory B-Cell Acute Lymphoblastic Leukemia, to be presented at the EHA Congress in June 2024.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:05 pm

AGIO

Agios Pharmaceuticals, Inc. (AGIO) announced its participation in the EHA2024 Hybrid Congress in Madrid, Spain, from June 13-16, 2024, where it will present data from its Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia during a plenary session. Additional presentations will include Quality of Life data from the ENERGIZE study and the design of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease. Agios will also host a virtual investor event on June 16, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:02 pm